Overview

A class action lawsuit has been filed against Dexcom, Inc. (“Dexcom” or the “Company”) (NASDAQ: DXCM) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Dexcom class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired DexCom securities between January 8, 2024, to July 25, 2024, both dates inclusive (the “Class Period”).  Investors have until October 21, 2024, to seek appointment as lead plaintiff of the DexCom class action lawsuit.

DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management.  DexCom’s G7 continuous glucose monitoring system, designed and distributed as an upgrade over the prior G6 model, was launched in early 2023.

The DexCom class action lawsuit alleges that Defendants, throughout the Class Period, provided investors with material information concerning DexCom’s expected revenue for the fiscal year 2024.  Defendants’ statements included, among other things, confidence in DexCom’s ability to capitalize on its growth potential to reach the projected record number of new patients and simultaneously outpace the prior fiscal year’s gross margins, while scaling customer conversion to the new G7 platform.  Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of DexCom’s salesforce; notably, that it was not truly equipped to execute on the Company’s perceived growth potential.  Such statements absent these material facts caused Plaintiff and other shareholders to purchase DexCom’s securities at artificially inflated prices.

*          *          *

If you purchased or otherwise acquired DexCom securities between January 8, 2024, to July 25, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the DexCom class action lawsuit is October 21, 2024.